Pipeline
COBIK is aimed to address the most pressing health challenges of the 21st century: antibiotic resistance and emerging viral diseases. Our pipeline is focused on bacteriophage-based solutions and viral vaccines.
We are developing potent antibacterial therapy and nanoparticle vaccine candidate pipeline by applying state-of-the-art bioengineering, genetic and molecular biology tools. Together, we deliver a broad spectrum of next generation therapeutics to combat the emerging threats of infectious disease.
Antibacterials
| Name | Target | Stage development pre-clinical clinical trial |
|---|---|---|
| COP-01/20 | multidrug-resistant S. epidermidis | pre-clinical |
| The powerful broad-spectrum phage COP-01/20 cocktail was developed to treat multidrug-resistant Staphylococcus epidermidis infections. Careful COP-01/20 phage selection and purification process provide excellent efficiency and safety profile. | ||
Vaccines
| Name | Target | Stage development pre-clinical clinical trial |
|---|---|---|
| CO-CoVac-01 | SARS CoV-2 | development |
| We developed the CO-CoVac-01 vaccine candidate against COVID-19 by using an innovative nanoparticle-based platform. CO-CoVac-01 mimics SARS-CoV-2 particles to deliver safe and robust protection. | ||
COBIK also believes in a more sustainable food system that does not require antibiotics. Therefore, we focus on the development of innovative foods using new technologies and production processes in the area of alternative proteins.
Novel foods technologies
| Name | Target | Stage components processes product |
|---|---|---|
| Alternative proteins | Dairy, Meat | processes |
| We emphasize on the development of the main components and provide innovative process solutions for the production of clean, safe alternative protein products without requiring antibiotic use. | ||
